Icon (ICLR) Stock Price, News & Analysis

Company Overview

ICON plc is a global contract research organization (CRO) specializing in the delivery of comprehensive drug development solutions to the pharmaceutical, biotechnology and medical device industries. Founded in 1990 and headquartered in Dublin, Ireland, the company provides a broad suite of services spanning clinical trial design, execution and management. By integrating scientific expertise with advanced data analytics and technology platforms, ICON supports its clients in bringing new therapies and medical products to market efficiently and in compliance with regulatory standards.

The company’s core offerings include clinical development services such as protocol design, patient recruitment and site management, safety and pharmacovigilance, biostatistics and data management. ICON also delivers specialized consulting solutions covering regulatory strategy, market access and health economics. Additionally, its real-world evidence and outcomes research capabilities draw on extensive patient data to inform product development decisions and optimize commercial strategies.

ICON operates in more than 50 countries with a network of regional offices across North America, Europe, Asia Pacific and Latin America. This global footprint enables the company to manage multi-site, multinational studies and to engage diverse patient populations. Over the years, ICON has expanded its reach and service portfolio through strategic acquisitions, most notably the integration of PRA Health Sciences in 2021, bolstering its capacity in late-stage clinical development and operational scale.

Originally established by John Climax, ICON has grown into one of the leading independent CROs under the leadership of Chief Executive Officer Peter Gray. The company’s senior management team combines deep industry experience with a commitment to innovation, quality and patient safety. As a publicly traded entity on the NASDAQ under the symbol ICLR, ICON remains focused on advancing clinical research through a client-centric approach and cutting-edge technological solutions.

Key Stats

• Today's Range: $148.59 to $155.38
• 50-Day Range: $126.62 to $151.58
• 52-Week Range: $125.10 to $347.72
• Volume: 865,630 shs
• Average Volume: 1.11 million shs
• Market Capitalization: $12.16 billion
• P/E Ratio: 16.40
• Dividend Yield: N/A
• Price Target: $198.08
• Consensus Rating: Moderate Buy

Icon Stock Analysis - MarketRank™

Icon scored higher than 90% of companies evaluated by MarketBeat, and ranked 134th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Icon has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 7 buy ratings, 7 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Icon has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 14.28%

Earnings Growth

Earnings for Icon are expected to grow by 14.28% in the coming year, from $13.38 to $15.29 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Icon is 16.40, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.92.

Price to Earnings Ratio vs. Sector

The P/E ratio of Icon is 16.40, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.05.

Price to Earnings Growth Ratio

Icon has a PEG Ratio of 1.85. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Icon has a P/B Ratio of 1.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.16% of the float of Icon has been sold short.

Short Interest Ratio / Days to Cover

Icon has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Icon has recently increased by 19.31%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Icon does not currently pay a dividend.

Dividend Growth

Icon does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.16% of the float of Icon has been sold short.

Short Interest Ratio / Days to Cover

Icon has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Icon has recently increased by 19.31%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.72

News Sentiment

Icon has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Icon this week, compared to 9 articles on an average week.

MarketBeat Follows

1 people have added Icon to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Icon insiders have not sold or bought any company stock.

Percentage Held by Insiders

44.00% of the stock of Icon is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

95.61% of the stock of Icon is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ICLR Stock Analysis - Frequently Asked Questions

How have ICLR shares performed this year?

Icon's stock was trading at $209.71 at the start of the year. Since then, ICLR stock has decreased by 28.2% and is now trading at $150.53.

How were Icon's earnings last quarter?

Icon Plc (NASDAQ:ICLR) announced its quarterly earnings results on Wednesday, April, 30th. The medical research company reported $3.19 EPS for the quarter, topping analysts' consensus estimates of $3.17 by $0.02. The company's revenue for the quarter was down 4.3% compared to the same quarter last year.
Read the conference call transcript.

Does Icon have any subsidiaries?

Icon subsidiaries include PRA Health Sciences, MedPass International, MeDiNova Research, MolecularMD, Mapi Group, Clinical Research Management, PMG Research, and more.

Who are Icon's major shareholders?

Icon's top institutional shareholders include Eldred Rock Partners LLC (0.07%), Financiere des Professionnels Fonds d investissement inc. (0.06%), Gateway Investment Advisers LLC (0.05%) and LVM Capital Management Ltd. MI (0.05%).

How do I buy shares of Icon?

Shares of ICLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Icon own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Icon investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Adobe (ADBE), Novo Nordisk A/S (NVO) and Jabil (JBL).

Company Calendar

• Last Earnings: 4/30/2025
• Today: 7/09/2025
• Next Earnings (Estimated): 7/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:ICLR
• CIK: 1060955
• Web: www.iconplc.com
• Phone: (531) 291-2000
• Fax: 353-1247-6260
• Employees: 41,900
• Year Founded: 1990

Price Target and Rating

• Average Price Target for Icon: $198.08
• High Price Target: $311.00
• Low Price Target: $150.00
• Potential Upside/Downside: +31.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): $9.18
• Trailing P/E Ratio: 16.40
• Forward P/E Ratio: 11.25
• P/E Growth: 1.85
• Net Income: $791.47 million
• Net Margins: 9.25%
• Pretax Margin: 10.10%
• Return on Equity: 11.46%
• Return on Assets: 6.49%

Debt

• Debt-to-Equity Ratio: 0.36
• Current Ratio: 1.27
• Quick Ratio: 1.27

Sales & Book Value

• Annual Sales: $8.28 billion
• Price / Sales: 1.47
• Cash Flow: $19.91 per share
• Price / Cash Flow: 7.56
• Book Value: $117.92 per share
• Price / Book: 1.28

Miscellaneous

• Outstanding Shares: 80,760,000
• Free Float: 45,224,000
• Market Cap: $12.16 billion
• Optionable: Optionable
• Beta: 1.17